Neutrophil elastase–syndecan-1 interaction

This entry refers to the association of neutrophil elastase—an abundant serine protease released by neutrophils during inflammation—and syndecan-1, a heparan sulfate proteoglycan present on epithelial and some endothelial surfaces. The **interaction is not a unique molecular species, but a functional event**: neutrophil elastase binds to the heparan sulfate chains of syndecan-1 on the cell surface, which localizes proteolytic activity, protects neutrophil elastase from inhibition by α1-antitrypsin, and focuses tissue injury to the pericellular space[1]. During inflammation or tissue damage, metalloproteinase-mediated *shedding* of syndecan-1 occurs, which can remove bound chemokines and facilitate resolution of neutrophilic inflammation[4]. Excessive syndecan-1 shedding, however, removes surface protection and allows neutrophil elastase to act freely, worsening tissue damage, as observed in chronic inflammatory and lung diseases[1][4]. This "target" is not a classical drug target (e.g., a receptor or enzyme), but the interaction is relevant for understanding inflammatory mechanisms and drug actions (notably those of neutrophil elastase inhibitors and heparin-like agents)[1][4]. The target as named—"Neutrophil elastase binding to Syndecan-1"—describes a *biological interaction*, not a druggable molecular entity. Therefore, it is not a canonical drug target, and is_incorrect is set to true for structured drug development purposes. For structured target information, refer to the individual entries for **Neutrophil elastase (HNE/ELANE)** and **Syndecan-1 (SDC1/CD138)**.

Other names

Neutrophil elastase binding to syndecan-1NE–syndecan-1 interactionHNE–syndecan-1 bindingNeutrophil elastase–Sdc1 complex

Neutrophil elastase inhibitors: block enzymatic activity of neutrophil elastase; Heparin: competitively inhibits the binding of neutrophil elastase to heparan sulfate proteoglycans like syndecan-1[1]